SMARCA4-DEFICIENT TUMOR
Clinical trials for SMARCA4-DEFICIENT TUMOR explained in plain language.
Never miss a new study
Get alerted when new SMARCA4-DEFICIENT TUMOR trials appear
Sign up with your email to follow new studies for SMARCA4-DEFICIENT TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising combo targets rare lung cancer in new trial
Disease control Not yet recruitingThis study tests a combination of anlotinib pills and standard chemotherapy for people with a rare, advanced lung cancer that lacks the SMARCA4 gene. The goal is to see if this combo can delay cancer growth and what side effects occur. About 28 adults with this specific tumor typ…
Matched conditions: SMARCA4-DEFICIENT TUMOR
Phase: PHASE2 • Sponsor: Zhijie Wang • Aim: Disease control
Last updated May 26, 2026 08:53 UTC
-
New drug combo targets rare, aggressive lung cancer in early trial
Disease control Not yet recruitingThis study tests a new two-in-one immunotherapy drug (iparomlimab and tuvonralimab) plus chemotherapy as a first treatment for people with a rare, advanced lung cancer that lacks the SMARCA4 gene. The goal is to see if this combination can shrink tumors or slow the cancer's growt…
Matched conditions: SMARCA4-DEFICIENT TUMOR
Phase: PHASE2 • Sponsor: Zhijie Wang • Aim: Disease control
Last updated May 22, 2026 14:01 UTC